Global Erythropoietin (EPO) Market Report 2020-30: COVID-19 Growth and Change

New York, December 21, 2020 (GLOBE NEWSWIRE) – Reportlinker.com announces the release of the “Global Erythropoietin (EPO) Market Report 2020-30: COVID-19 Growth and Change” – https://www.reportlinker .com / p05999219 /? utm_source = GNW
01 billion in 2019 to $ 0.95 billion in 2020 at a compound annual growth rate (CAGR) of -6.27%. The decline is primarily due to the outbreak of COVID-19 which has resulted in restrictive restraint measures that include social isolation, remote working, and the closure of industries and other commercial activities leading to operational challenges. The entire supply chain was disrupted, negatively affecting the market. The market is then expected to recover and reach $ 2.27 billion in 2023 at a CAGR of 33.9%.

The erythropoietin (EPO) market involves the sale of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that produce erythropoietin biosimilars. Erythropoietin (EPO) is a hormone produced by kidneys and plays a vital role in the production of red blood cells, which carry oxygen from the lungs to the rest of the body. Lack of adequate erythropoietin leads to low red blood cells, which may lead to anemia. The drugs erythropoietin (EPO) are used for treatment for anemia, kidney disorders, cancer and other conditions.

In August 2018, STADA Arzneimittel AG, a German pharmaceutical company, received majority (51.34%) bets at Arzneimittel Bioceuticals AG for an undisclosed amount. The acquisition is expected to expand STADA Arzneimittel AG’s presence in the similar bios sector. Arzneimittel AG Bioceuticals licenses marketing rights to epoetin zeta and epoetin bios similar to STADA Arzneimittel AG. Bioceuticals Arzneimittel AG is a German company involved in the manufacture and marketing of active pharmaceutical ingredients including erythropoietin biosimilars.

The erythropoietin market covered in this report is segmented by product in epoetin-alfa; epoetin-beta; darbepoetin-alpha; others and by qualifying for cancer; hematology; renal disease; neurology; others.

Strict regulations imposed on the production and sale of erythropoietin drugs are anticipated to hamper the growth of the erythropoietin market over the forecast period. For example, in the European Community (EC), technologically advanced medicinal products manufactured using a biotechnological process such as recombinant DNA technology should comply with a marketing authorization (MA) under the provisions of Regulation (EC) No. 726/04 issued by the EC . The regulatory policy for biosimilars is complex and in Europe is largely governed by guidelines issued by the European Medicines Agency (EMEA). In addition, recombinant human erythropoietin (rHuEPO) must meet additional class-specific guidelines apart from regulations on quality, clinical and non-clinical issues developed by the EMEA.

Chronic kidney disease incidence is forecast to drive demand for the erythropoietin market over the coming years. According to Brazilian Journal of Nephrology statistics published in February 2019, kidney disease is a global public healthcare problem affecting over 750 million people worldwide. In addition, according to a Centers for Disease Control and Prevention report published on chronic kidney disease in the United States, in 2019, an estimated 15% of adults in the U.S., or 37 million people, have chronic kidney disease (CKD). CKD is more common in people aged 65 and over (38%) than in people aged 45-64 (13%) and 18-44 (7%). Chronic kidney diseases lead to an anemic condition which in turn increases the demand for erythropoietin to curb the condition, thereby driving the market revenue.
Read the full report: https://www.reportlinker.com/p05999219/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker captures and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

.Source